Skip to Main Content

Author Details

Sebastiaan Remmers
Erasmus MC Cancer Institute, University Medical Center Rotterdam
2018
58
10
PMIDPaper TitleJournal TitlePublished Year
37414703Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data.Eur Urol2024
37919190Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.Eur Urol2024
37607322Performance of magnetic resonance imaging-based prostate cancer risk calculators and decision strategies in two large European medical centres.BJU Int2024
36245015External validation of the Rotterdam prostate cancer risk calculator within a high-risk Dutch clinical cohort.World J Urol2023
37695584Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy.JAMA Netw Open2023
37690917From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of Life.Eur Urol Oncol2023
37088597Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer.Eur Urol2023
37187725The Patient Journey from Randomization to Detection of Prostate Cancer and Death: Results from ERSPC Rotterdam.Eur Urol Open Sci2023
36980749Sex Differences in Survival from Neuroendocrine Neoplasia in England 2012-2018: A Retrospective, Population-Based Study.Cancers (Basel)2023
37140551Biopsy prostate cancer perineural invasion and tumour load are associated with positive posterolateral margins at radical prostatectomy: implications for planning of nerve-sparing surgery.Histopathology2023
37305629A literature review to understand health literacy in men with prostate cancer on active surveillance.Transl Androl Urol2023
37268512The Europa Uomo Patient Reported Outcome Study 2.0-Prostate Cancer Patient-reported Outcomes to Support Treatment Decision-making.Eur Urol Focus2023
37032279Urinary Incontinence and Sexual Function After the Introduction of NeuroSAFE in Radical Prostatectomy for Prostate Cancer.Eur Urol Focus2023
37029074A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer.Eur Urol2023
36408660Shifting risk-stratified early prostate cancer detection to a primary healthcare setting.BJU Int2023
36519924Sexual and urinary function in prostate cancer clinical studies and the Europa Uomo Patient Reported Outcome Study: does it match?Minerva Urol Nephrol2023
36631536The transition from transrectal to transperineal prostate biopsy without antibiotic prophylaxis: Cancer detection rates and complication rates.Prostate Cancer Prostatic Dis2023
34453109Initial Prostate Health Index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study.Prostate Cancer Prostatic Dis2022
35384019Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies.Histopathology2022
35803346Predictive Value of Cribriform and Intraductal Carcinoma for the Nomogram-based Selection of Prostate Cancer Patients for Pelvic Lymph Node Dissection.Urology2022
35437217A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.Eur Urol Oncol2022
35341658A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging-directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naïve Men.Eur Urol2022
35536200NeuroSAFE in radical prostatectomy increases the rate of nerve-sparing surgery without affecting oncological outcome.BJU Int2022
35464652Development of a prediction model in female pure or predominant urge urinary incontinence: a retrospective cohort study.Ther Adv Urol2022
35629173Secondary Treatment for Men with Localized Prostate Cancer: A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform.J Pers Med2022
35813248External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort.Eur Urol Open Sci2022
35850672Cross-cultural differences in men on active surveillance' anxiety: a longitudinal comparison between Italian and Dutch patients from the Prostate cancer Research International Active Surveillance study.BMC Urol2022
36429059Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling.Cells2022
35911085Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam.Eur Urol Open Sci2022
35950035Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification.BJUI Compass2022
35157140Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy.Virchows Arch2022
34717190Improving the prediction of biochemical recurrence after radical prostatectomy with the addition of detailed pathology of the positive surgical margin and cribriform growth.Ann Diagn Pathol2022
33207138Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer.J Urol2021
33493004Reply by Authors.J Urol2021
33563084Impact of cancer screening on metastasis: A prostate cancer case study.J Med Screen2021
33833378What is the effect of MRI with targeted biopsies on the rate of patients discontinuing active surveillance? A reflection of the use of MRI in the PRIAS study.Prostate Cancer Prostatic Dis2021
35098168Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data.Eur Urol Open Sci2021
34977692Updating the Rotterdam Prostate Cancer Risk Calculator with Invasive Cribriform and/or Intraductal Carcinoma for Men with a Prior Negative Biopsy.Eur Urol Open Sci2021
34934964Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer.Eur Urol Open Sci2021
34374190A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant?BJU Int2021
33965292Rotterdam mobile phone app including MRI data for the prediction of prostate cancer: A multicenter external validation.Eur J Surg Oncol2021
34175896Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients.Mod Pathol2021
34337525External Validation of Two Nomograms Developed for <sup>68</sup>Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer <sup>18</sup>F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?Eur Urol Open Sci2021
34169337External validation of two MRI-based risk calculators in prostate cancer diagnosis.World J Urol2021
33281109Europa Uomo Patient Reported Outcome Study (EUPROMS): Descriptive Statistics of a Prostate Cancer Survey from Patients for Patients.Eur Urol Focus2021
33079252Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance: 3-year follow-up from PRIAS-JAPAN.World J Urol2021
31439369Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.Eur Urol2020
33111657The Influence of Poststudy Action Congruency on Memory Consolidation.Exp Psychol2020
33321791Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies.J Pers Med2020
32589489Reply by Authors.J Urol2020
  • 1 - 50 of 58

Recommended Authors

Robert T Dess
University of Michigan ann arbor
Career Start Year 2016
Number of shared co-authors 3
R Jeffrey Karnes
Mayo Clinic
Career Start Year 2013
Number of shared co-authors 3
Neil Mendhiratta
National Cancer Institute, National Institutes of Health
Career Start Year 2013
Number of shared co-authors 0
Adam B Weiner
Northwestern University Feinberg School of Medicine
Career Start Year 2013
Number of shared co-authors 0
Simpa S Salami
University of Michigan Medical School ann arbor
Career Start Year 2012
Number of shared co-authors 0
Brandon A Mahal
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
Career Start Year 2011
Number of shared co-authors 8
Devin N Patel
university of california san diego School of Medicine
Career Start Year 2011
Number of shared co-authors 1
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Career Start Year 2010
Number of shared co-authors 6
Michael A Liss
University of Texas Health San Antonio
Career Start Year 2008
Number of shared co-authors 1
Jeffrey J Tosoian
Vanderbilt University Medical Center
Career Start Year 2008
Number of shared co-authors 1
Alastair D Lamb
University of Oxford
Career Start Year 2007
Number of shared co-authors 4
Declan G Murphy
Peter MacCallum Cancer Centre, University of Melbourne
Career Start Year 2005
Number of shared co-authors 11
Marco Randazzo
Winterthur Cantonal Hospital
Career Start Year 2005
Number of shared co-authors 5
Alejandro Berlin
University of Toronto, Princess Margaret Cancer Centre
Career Start Year 2004
Number of shared co-authors 11
Ashley E Ross
Northwestern University
Career Start Year 2003
Number of shared co-authors 2
Robert Jeffrey Karnes
Mayo Clinic
Career Start Year 2000
Number of shared co-authors 8
Vincent J Gnanapragasam
University of Cambridge
Career Start Year 1999
Number of shared co-authors 4
Jim C Hu
Weill Cornell Medical Center
Career Start Year 1998
Number of shared co-authors 6
Niall M Corcoran
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1997
Number of shared co-authors 2
Todd M Morgan
University of Michigan ann arbor
Career Start Year 1997
Number of shared co-authors 9
Stephen J Freedland
Cedars-Sinai Medical Center
Career Start Year 1996
Number of shared co-authors 9
Inge M van Oort
Radboud University Medical Center
Career Start Year 1995
Number of shared co-authors 13
Markus Graefen
University Hospital Frankfurt, Goethe University Frankfurt am Main
Career Start Year 1993
Number of shared co-authors 12
Paul L Nguyen
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Career Start Year 1990
Number of shared co-authors 6
Fred Saad
University of Montreal Health Center
Career Start Year 1990
Number of shared co-authors 10
Neil E Fleshner
University of Toronto
Career Start Year 1989
Number of shared co-authors 14
Mark Frydenberg
Monash University
Career Start Year 1988
Number of shared co-authors 11
Freddie C Hamdy
University of Oxford
Career Start Year 1987
Number of shared co-authors 10
Bruce J Trock
Johns Hopkins University School of Medicine
Career Start Year 1984
Number of shared co-authors 8
Eric A Klein
Cleveland Clinic
Career Start Year 1984
Number of shared co-authors 9

Collaborators

Monique J Roobol
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Co-authored papers 47
Geert J L H van Leenders
Erasmus MC Cancer Institute, University Medical Center
Co-authored papers 15
Charlotte F Kweldam
Anser Prostate Operation Clinic, Maasstad Hospital
Co-authored papers 5
Mieke Van Hemelrijck
School of Cancer and Pharmaceutical Sciences, King's College London
Co-authored papers 4
Theodorus H van der Kwast
University Health Network, University of Toronto
Co-authored papers 4
Maciej Kwiatkowski
University of Basel, Academic Hospital Braunschweig
Co-authored papers 3
Esther I Verhoef
Erasmus University Medical Center
Co-authored papers 3
Derya Tilki
Universitatsklinikum Hamburg-Eppendorf
Co-authored papers 2
Alex Asiimwe
Bayer Pharma AG
Co-authored papers 2
Alberto Briganti
IRCCS San Raffaele Scientific Institute
Co-authored papers 2
Giorgio Gandaglia
IRCCS San Raffaele Scientific Institute, Italy Vita-Salute San Raffaele University
Co-authored papers 2
Asieh Golozar
Northeastern University
Co-authored papers 1
Muhammad Imran Omar
University of Aberdeen
Co-authored papers 1
Thomas Falconer
Columbia University
Co-authored papers 1
Emma J Smith
University of Guelph
Co-authored papers 1
Roderick C N van den Bergh
St. Antonius Hospital
Co-authored papers 1
Carlos Areia
University of Oxford
Co-authored papers 1
Hendrik Van Poppel
University Hospitals Leuven
Co-authored papers 1
Tim Hulsen
Department of Hospital Services & Informatics
Co-authored papers 1
Eleni-Rosalina Andrinopoulou
Erasmus MC Cancer Institute, Erasmus University Medical Center
Co-authored papers 1
Riccardo Campi
Careggi University Hospital
Co-authored papers 1
Philip Cornford
Liverpool University Hospitals
Co-authored papers 1
Kees van Bochove
Biosystematics Group Wageningen University Wageningen The Netherlands.
Co-authored papers 1
Bertrand De Meulder
European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM
Co-authored papers 1
Carl Steinbeisser
Co-authored papers 1
Francesco Pellegrino
Urological Research Institute, IRCCS San Raffaele Hospital
Co-authored papers 1
Qi Feng
Astellas Pharma, Inc.
Co-authored papers 1
Guido Jenster
Erasmus University Medical Center
Co-authored papers 1
Vasileios I Sakalis
Hippokrateion General Hospital of Thessaloniki
Co-authored papers 1
Marek Oja
Institute of Computer Science, University of Tartu
Co-authored papers 1
Release 1.2